Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.
2.

A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.

Beernink PT, Ispasanie E, Lewis LA, Ram S, Moe GR, Granoff DM.

J Infect Dis. 2019 Mar 15;219(7):1130-1137. doi: 10.1093/infdis/jiy609.

PMID:
30346576
3.

Molecular characterization of two sub-family specific monoclonal antibodies to meningococcal Factor H binding protein.

Lo Passo C, Zippilli L, Angiolillo A, Costa I, Pernice I, Galbo R, Felici F, Beernink PT.

Heliyon. 2018 Apr 3;4(4):e00591. doi: 10.1016/j.heliyon.2018.e00591. eCollection 2018 Apr.

4.

Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp.

López-Sagaseta J, Beernink PT, Bianchi F, Santini L, Frigimelica E, Lucas AH, Pizza M, Bottomley MJ.

Nat Commun. 2018 Feb 6;9(1):528. doi: 10.1038/s41467-018-02827-7.

5.

Charge neutralization in the active site of the catalytic trimer of aspartate transcarbamoylase promotes diverse structural changes.

Endrizzi JA, Beernink PT.

Protein Sci. 2017 Nov;26(11):2221-2228. doi: 10.1002/pro.3277. Epub 2017 Sep 30.

6.

Neisseria meningitidis factor H-binding protein bound to monoclonal antibody JAR5: implications for antibody synergy.

Malito E, Lo Surdo P, Veggi D, Santini L, Stefek H, Brunelli B, Luzzi E, Bottomley MJ, Beernink PT, Scarselli M.

Biochem J. 2016 Dec 15;473(24):4699-4713. Epub 2016 Oct 26.

7.

Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.

Granoff DM, Giuntini S, Gowans FA, Lujan E, Sharkey K, Beernink PT.

JCI Insight. 2016 Sep 8;1(14):e88907. doi: 10.1172/jci.insight.88907.

8.

Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.

Giuntini S, Granoff DM, Beernink PT, Ihle O, Bratlie D, Michaelsen TE.

Clin Vaccine Immunol. 2016 Aug 5;23(8):698-706. doi: 10.1128/CVI.00193-16. Print 2016 Aug.

9.

Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.

Rossi R, Konar M, Beernink PT.

Infect Immun. 2016 May 24;84(6):1735-1742. doi: 10.1128/IAI.01491-15. Print 2016 Jun.

10.

A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Konar M, Pajon R, Beernink PT.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14823-8. doi: 10.1073/pnas.1507829112. Epub 2015 Nov 16.

11.

Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Giuntini S, Beernink PT, Granoff DM.

Vaccine. 2015 Dec 16;33(51):7168-7175. doi: 10.1016/j.vaccine.2015.10.135. Epub 2015 Nov 10.

12.

Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Rossi R, Beernink PT, Giuntini S, Granoff DM.

Clin Vaccine Immunol. 2015 Dec;22(12):1227-34. doi: 10.1128/CVI.00474-15. Epub 2015 Sep 30.

13.

A Newly-Identified Polymorphism in Rhesus Macaque Complement Factor H Modulates Binding Affinity for Meningococcal FHbp.

Konar M, Beernink PT, Granoff DM.

PLoS One. 2015 Aug 18;10(8):e0135996. doi: 10.1371/journal.pone.0135996. eCollection 2015.

14.

Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein.

Beernink PT, Giuntini S, Costa I, Lucas AH, Granoff DM.

MBio. 2015 Jun 23;6(3):e00842. doi: 10.1128/mBio.00842-15.

15.

A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens.

Konar M, Rossi R, Walter H, Pajon R, Beernink PT.

PLoS One. 2015 Jun 9;10(6):e0128185. doi: 10.1371/journal.pone.0128185. eCollection 2015.

16.

Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.

Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT.

J Infect Dis. 2015 Sep 1;212(5):784-92. doi: 10.1093/infdis/jiv081. Epub 2015 Feb 12.

17.

Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM.

Clin Vaccine Immunol. 2014 Nov;21(11):1505-11. doi: 10.1128/CVI.00517-14. Epub 2014 Sep 3.

18.

Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice.

Rossi R, Granoff DM, Beernink PT.

Vaccine. 2013 Nov 4;31(46):5451-7. doi: 10.1016/j.vaccine.2013.08.099. Epub 2013 Sep 11.

19.

Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Granoff DM, Ram S, Beernink PT.

Clin Vaccine Immunol. 2013 Aug;20(8):1099-107. doi: 10.1128/CVI.00260-13. Epub 2013 Jun 5. Review.

20.

Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Konar M, Granoff DM, Beernink PT.

J Infect Dis. 2013 Aug 15;208(4):627-36. doi: 10.1093/infdis/jit239. Epub 2013 May 28.

21.

Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.

Pajon R, Beernink PT, Granoff DM.

Infect Immun. 2012 Aug;80(8):2667-77. doi: 10.1128/IAI.00103-12. Epub 2012 May 21. Erratum in: Infect Immun. 2014 Apr;82(4):1742.

22.

The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM.

PLoS Pathog. 2012;8(5):e1002688. doi: 10.1371/journal.ppat.1002688. Epub 2012 May 10.

23.

Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity.

Giuntini S, Beernink PT, Reason DC, Granoff DM.

PLoS One. 2012;7(3):e34272. doi: 10.1371/journal.pone.0034272. Epub 2012 Mar 26.

24.

A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM.

J Immunol. 2011 Mar 15;186(6):3606-14. doi: 10.4049/jimmunol.1003470. Epub 2011 Feb 16.

25.

Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Dunphy KY, Beernink PT, Brogioni B, Granoff DM.

Infect Immun. 2011 Jan;79(1):353-9. doi: 10.1128/IAI.00849-10. Epub 2010 Nov 1.

26.

Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding.

Beernink PT, Shaughnessy J, Ram S, Granoff DM.

Clin Vaccine Immunol. 2010 Jul;17(7):1074-8. doi: 10.1128/CVI.00103-10. Epub 2010 Jun 2.

27.

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates.

Pajon R, Beernink PT, Harrison LH, Granoff DM.

Vaccine. 2010 Feb 25;28(9):2122-9. doi: 10.1016/j.vaccine.2009.12.027. Epub 2009 Dec 29.

28.

The modular architecture of meningococcal factor H-binding protein.

Beernink PT, Granoff DM.

Microbiology. 2009 Sep;155(Pt 9):2873-83. doi: 10.1099/mic.0.029876-0. Epub 2009 Jul 2.

29.

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM.

J Infect Dis. 2009 May 1;199(9):1360-8. doi: 10.1086/597806.

30.

A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups.

Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D.

Mol Immunol. 2009 May;46(8-9):1647-53. doi: 10.1016/j.molimm.2009.02.021. Epub 2009 Mar 14.

31.

Identification of a thermo-regulated glutamine-binding protein from Yersinia pestis.

Cosman M, Pesavento JB, Zemla A, Beernink PT, Balhorn R, Barsky D.

Protein Pept Lett. 2008;15(9):887-94.

PMID:
18991762
32.

Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.

Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM.

Infect Immun. 2008 Sep;76(9):4232-40. doi: 10.1128/IAI.00367-08. Epub 2008 Jun 30.

33.

Applications of functional protein microarrays: identifying protein-protein interactions in an array format.

Coleman MA, Beernink PT, Camarero JA, Albala JS.

Methods Mol Biol. 2007;385:121-30.

PMID:
18365708
34.

Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.

Beernink PT, Granoff DM.

Infect Immun. 2008 Jun;76(6):2568-75. doi: 10.1128/IAI.00033-08. Epub 2008 Mar 24.

35.
37.

Specificity of protein interactions mediated by BRCT domains of the XRCC1 DNA repair protein.

Beernink PT, Hwang M, Ramirez M, Murphy MB, Doyle SA, Thelen MP.

J Biol Chem. 2005 Aug 26;280(34):30206-13. Epub 2005 Jun 28.

38.

High-throughput, fluorescence-based screening for soluble protein expression.

Coleman MA, Lao VH, Segelke BW, Beernink PT.

J Proteome Res. 2004 Sep-Oct;3(5):1024-32.

PMID:
15473692
39.

Thermodynamic analysis of the dissociation of the aldolase tetramer substituted at one or both of the subunit interfaces.

Tolan DR, Schuler B, Beernink PT, Jaenicke R.

Biol Chem. 2003 Oct-Nov;384(10-11):1463-71.

PMID:
14669989
40.

Identification of chromatin-related protein interactions using protein microarrays.

Coleman MA, Miller KA, Beernink PT, Yoshikawa DM, Albala JS.

Proteomics. 2003 Nov;3(11):2101-7.

PMID:
14595808
41.

Spatial clustering of isozyme-specific residues reveals unlikely determinants of isozyme specificity in fructose-1,6-bisphosphate aldolase.

Pezza JA, Choi KH, Berardini TZ, Beernink PT, Allen KN, Tolan DR.

J Biol Chem. 2003 May 9;278(19):17307-13. Epub 2003 Feb 28.

42.

Application of In Vitro Protein Expression to Human Prote.

Beernink PT, Krupka SS, Lao V, Martin G, Coleman MA.

ScientificWorldJournal. 2002 May 21;2:73-74. doi: 10.1100/tsw.2002.35. eCollection 2002. No abstract available.

44.

Two divalent metal ions in the active site of a new crystal form of human apurinic/apyrimidinic endonuclease, Ape1: implications for the catalytic mechanism.

Beernink PT, Segelke BW, Hadi MZ, Erzberger JP, Wilson DM 3rd, Rupp B.

J Mol Biol. 2001 Apr 6;307(4):1023-34.

PMID:
11286553
45.
46.
47.

Assessment of the allosteric mechanism of aspartate transcarbamoylase based on the crystalline structure of the unregulated catalytic subunit.

Beernink PT, Endrizzi JA, Alber T, Schachman HK.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5388-93.

48.

Disruption of the aldolase A tetramer into catalytically active monomers.

Beernink PT, Tolan DR.

Proc Natl Acad Sci U S A. 1996 May 28;93(11):5374-9.

49.

Subunit interface mutants of rabbit muscle aldolase form active dimers.

Beernink PT, Tolan DR.

Protein Sci. 1994 Sep;3(9):1383-91.

50.

Construction of a high-copy "ATG vector" for expression in Escherichia coli.

Beernink PT, Tolan DR.

Protein Expr Purif. 1992 Aug;3(4):332-6.

PMID:
1422227

Supplemental Content

Loading ...
Support Center